ATC code C: Cardiovascular system |
---|
|
Other ATC codes |
ATC code C Cardiovascular system is a section of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products. [1] [2] [3] [4]
Codes for
veterinary use (
ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QC.
[5]
National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.
Major chemical drug groups – based upon the
Anatomical Therapeutic Chemical Classification System | |
---|---|
gastrointestinal tract / metabolism ( A) | |
blood and blood forming organs ( B) | |
cardiovascular system ( C) | |
skin ( D) | |
genitourinary system ( G) | |
endocrine system ( H) | |
infections and infestations ( J, P, QI) | |
malignant disease ( L01–L02) | |
immune disease ( L03–L04) | |
muscles,
bones, and joints ( M) | |
brain and nervous system ( N) |
|
respiratory system ( R) | |
sensory organs ( S) | |
other ATC ( V) | |
Bufadienolides |
| ||||||
---|---|---|---|---|---|---|---|
Cardenolides |
| ||||||
|
Channel blockers |
| ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Receptor
agonists and antagonists |
| ||||||||||||
Ion transporters |
| ||||||||||||
|
Cardiac stimulants excluding cardiac glycosides (
C01C) | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Adrenergic and dopaminergic agents |
| ||||||||||||||
Phosphodiesterase inhibitors ( PDE3I) | |||||||||||||||
Other cardiac stimulants | |||||||||||||||
|
Nitrovasodilators | |
---|---|
Quinolone vasodilators | |
Others | |
|
Sympatholytics (antagonize α-adrenergic vasoconstriction) | |||||
---|---|---|---|---|---|
Other antagonists |
| ||||
|
Nitrovasodilator (arterioles and venules) | |
---|---|
Hydrazinophthalazines (arterioles) | |
Potassium channel openers (arterioles) | |
Calcium channel blockers (arterioles) |
|
|
Sulfonamides (and etacrynic acid) |
| ||||||||
---|---|---|---|---|---|---|---|---|---|
Potassium-sparing (at CD) |
| ||||||||
Osmotic diuretics ( PT, DL) | |||||||||
Vasopressin receptor inhibitors ( DCT and CD) | |||||||||
Other | |||||||||
Combination products | |||||||||
|
Phenylethanolamine derivatives | |
---|---|
Alpha blockers |
|
Niacin and derivatives | |
Purine derivatives | |
Ergot alkaloids | |
Other peripheral vasodilators |
Antihemorrhoidals for topical use |
| ||||||
---|---|---|---|---|---|---|---|
Antivaricose therapy |
| ||||||
Capillary stabilising agents |
|
Beta blockers (
C07) | |
---|---|
β, non-selective | |
β1-selective | |
β2-selective | |
α1- + β-selective | |
|
Calcium |
| ||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Potassium |
| ||||||||||||||||||||||||
Sodium |
| ||||||||||||||||||||||||
Chloride |
| ||||||||||||||||||||||||
Others |
| ||||||||||||||||||||||||
ACE inhibitors ("-pril") |
|
---|---|
AIIRAs ("-sartan") | |
Renin inhibitors ("-kiren") | |
Dual ACE/ NEP inhibitors | |
Neprilysin inhibitors | |
|
GI tract |
| ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Liver |
| ||||||||||||
Blood vessels |
| ||||||||||||
Combinations | |||||||||||||
Other | |||||||||||||
|
ATC code C: Cardiovascular system |
---|
|
Other ATC codes |
ATC code C Cardiovascular system is a section of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products. [1] [2] [3] [4]
Codes for
veterinary use (
ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QC.
[5]
National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.
Major chemical drug groups – based upon the
Anatomical Therapeutic Chemical Classification System | |
---|---|
gastrointestinal tract / metabolism ( A) | |
blood and blood forming organs ( B) | |
cardiovascular system ( C) | |
skin ( D) | |
genitourinary system ( G) | |
endocrine system ( H) | |
infections and infestations ( J, P, QI) | |
malignant disease ( L01–L02) | |
immune disease ( L03–L04) | |
muscles,
bones, and joints ( M) | |
brain and nervous system ( N) |
|
respiratory system ( R) | |
sensory organs ( S) | |
other ATC ( V) | |
Bufadienolides |
| ||||||
---|---|---|---|---|---|---|---|
Cardenolides |
| ||||||
|
Channel blockers |
| ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Receptor
agonists and antagonists |
| ||||||||||||
Ion transporters |
| ||||||||||||
|
Cardiac stimulants excluding cardiac glycosides (
C01C) | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Adrenergic and dopaminergic agents |
| ||||||||||||||
Phosphodiesterase inhibitors ( PDE3I) | |||||||||||||||
Other cardiac stimulants | |||||||||||||||
|
Nitrovasodilators | |
---|---|
Quinolone vasodilators | |
Others | |
|
Sympatholytics (antagonize α-adrenergic vasoconstriction) |
| ||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Other antagonists |
| ||||||||||||||||||||||||||
|
Nitrovasodilator (arterioles and venules) | |
---|---|
Hydrazinophthalazines (arterioles) | |
Potassium channel openers (arterioles) | |
Calcium channel blockers (arterioles) |
|
|
Sulfonamides (and etacrynic acid) |
| ||||||||
---|---|---|---|---|---|---|---|---|---|
Potassium-sparing (at CD) |
| ||||||||
Osmotic diuretics ( PT, DL) | |||||||||
Vasopressin receptor inhibitors ( DCT and CD) | |||||||||
Other | |||||||||
Combination products | |||||||||
|
Phenylethanolamine derivatives | |
---|---|
Alpha blockers |
|
Niacin and derivatives | |
Purine derivatives | |
Ergot alkaloids | |
Other peripheral vasodilators |
Antihemorrhoidals for topical use |
| ||||||
---|---|---|---|---|---|---|---|
Antivaricose therapy |
| ||||||
Capillary stabilising agents |
|
Beta blockers (
C07) | |
---|---|
β, non-selective | |
β1-selective | |
β2-selective | |
α1- + β-selective | |
|
Calcium |
| ||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Potassium |
| ||||||||||||||||||||||||
Sodium |
| ||||||||||||||||||||||||
Chloride |
| ||||||||||||||||||||||||
Others |
| ||||||||||||||||||||||||
ACE inhibitors ("-pril") |
|
---|---|
AIIRAs ("-sartan") | |
Renin inhibitors ("-kiren") | |
Dual ACE/ NEP inhibitors | |
Neprilysin inhibitors | |
|
GI tract |
| ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Liver |
| ||||||||||||
Blood vessels |
| ||||||||||||
Combinations | |||||||||||||
Other | |||||||||||||
|